Kidney International® Cutting Back on Low-value Healthcare Practices Supports Sustainable Kidney Care This mini review, part of a collaboration between ISN Emerging Leaders Program members and Kidney International® to promote green nephrology, emphasizes the urgent need for climate action, noting that healthcare contributes 5.5% of global carbon emissions. It highlights the importance of reducing low-value care...
Read all global trial selections from the ISN-ACT initiative here. The “trial of the month” is available in several languages. In addition, selected clinical trials are demystified for the layperson. ISN-ACT Global Trials Focus Subgroup member Nikolay Bulanov summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus’s latest trial selections. Efficacy and safety of...
Kidney International® Executive Summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis Since the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published, important data concerning anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) has become available. These include the regulatory approval of avacopan for ANCA-AAV...
Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides are a heterogeneous group of rare autoimmune conditions that cause inflammation of blood vessels with various manifestations mainly involving the kidney and lung. The incidence is 10-20 cases per million population, mainly affecting people in the 5th decade of life. ANCA-associated Vasculitis includes three main diseases: granulomatosis with polyangiitis, microscopic...
